Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$63.99 USD

63.99
3,019,526

+2.89 (4.73%)

Updated Oct 31, 2025 04:00 PM ET

After-Market: $63.88 -0.11 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know

by Zacks Equity Research

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.

Zacks Equity Research

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

by Zacks Equity Research

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $67.21, denoting a +1.04% move from the preceding trading day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Moves -2.24%: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $72.31, marking a -2.24% move from the previous day.

Kanishka Das headshot

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

by Kanishka Das

Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.

Zacks Equity Research

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $68.29, indicating a -6.54% shift from the previous trading day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $60.62, marking a -2.38% move from the previous day.

Zacks Equity Research

CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU

by Zacks Equity Research

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.

Zacks Equity Research

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Ekta Bagri headshot

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025

by Ekta Bagri

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.

Kinjel Shah headshot

Vertex Plunges Around 24% in Six Months: How to Play the Stock

by Kinjel Shah

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the previous trading day.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.